$ROIV · Roivant Sciences Ltd.
Roivant reported Q2 FY2026 (ended September 30, 2026) results: net revenue of $35.1M (vs $1.6M a year ago), driven by $31.0M in LISRAYA product revenue in its first 5 weeks post-FDA approval. GAAP net loss attributable to Roivant was $191.6M ($0.27/share), including $95.9M in Genevant RSU/option distributions tied to the Moderna settlement. Consolidated cash, equivalents and marketable securities stood at $4.2B.
- LISRAYA net product revenue was $31.0M in its first 5 weeks of launch.
- IMVT-1402 600mg met ACR20 primary endpoint in D2T RA (92.5% vs 75.6% placebo, p=0.0139).
- Brepocitinib met primary and all key secondary endpoints in Phase 3 CLARITY-1 and CLARITY-2 NIU trials.
- Mosliciguat Phase 2 PHocus met primary endpoint with -56.3% placebo-adjusted PVR reduction (p<0.0001).
- Consolidated cash, equivalents and marketable securities totaled $4.2B as of September 30, 2026.
Extended-hours last trade $40.35, up +3.78% vs the $38.88 regular close, signaling a positive after-hours reaction to the LISRAYA launch and IMVT-1402 data.
Roivant's first commercial product launch and a positive registrational-trial readout mark a pivotal transition from clinical-stage to commercial biotech.
Roivant's LISRAYA launch and IMVT-1402 D2T RA readout position it against immunology peers with late-stage FcRn and TYK2/JAK1 assets.
IMVT-1402 300mg did not separate from placebo (75.0% vs 75.6%, p=0.9426), and the company expects it is unlikely to advance IMVT-1402 further in Sjögren's disease beyond the ongoing Phase 2 trial.